MBZUAI and Cleveland Clinic Abu Dhabi jointly showcased AI applications to address UAE healthcare challenges, focusing on diabetes, heart disease, and vision loss. The event highlighted AI-powered robots for surgical tool guidance, autonomous ultrasound systems, and AI-based eye diagnostics for early disease detection. Researchers presented advances in AI-powered intrabody navigation, robotic ultrasound imaging, and AI-based oculomics. Why it matters: These AI innovations have the potential to transform healthcare delivery in the UAE, improving surgical outcomes, democratizing access to diagnostic imaging, and enabling earlier disease detection.
SEHA and MBZUAI have signed an MoU to integrate AI into medical care and enhance clinical expertise. They will collaborate on AI-driven solutions for quantifying COVID-19 infection severity and study its long-term impact on UAE residents. The partnership will also focus on diagnosis and treatment methods for acute kidney injury, coronary artery disease, fetal health, and AI-driven point of care ultrasound. Why it matters: This collaboration between a major healthcare provider and an AI university in the UAE could lead to advancements in AI-driven healthcare solutions and improve patient outcomes.
Cleveland Clinic Abu Dhabi and MBZUAI have signed an MoU to collaborate on research and education initiatives. The partnership aims to create opportunities such as joint research projects and mentorship programs for students. Both institutions will leverage their expertise to explore AI applications in healthcare, focusing on areas like diagnostics and digital twins. Why it matters: The collaboration will strengthen Abu Dhabi's position as a hub for AI-enabled healthcare innovation and talent development.
Technology Innovation Institute (TII) and Burjeel Medical City (BMC) are partnering to develop novel immunotherapy solutions for cancer treatment, focusing on T-cell based therapeutics like CAR-T and TIL therapy. In the first phase, TII will construct a computational platform to identify patient-specific antigens from single-cell transcriptomics data, enabling the design of CAR-T cells. The two-year partnership aims to boost the body's immune system to fight cancer and personalize cancer therapies using TII's technologies. Why it matters: This collaboration signifies the UAE's commitment to advancing cancer care through collaborative research and innovative solutions, potentially establishing the country as a leader in personalized oncology treatments.